These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 12009943)

  • 1. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
    Froidevaux S; Eberle AN; Christe M; Sumanovski L; Heppeler A; Schmitt JS; Eisenwiener K; Beglinger C; Mäcke HR
    Int J Cancer; 2002 Apr; 98(6):930-7. PubMed ID: 11948475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
    de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
    Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
    Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
    Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
    Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
    Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
    Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
    Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
    Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
    Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.